Yohimban-16-carboxylicacid,11,17-dimethoxy-18-[[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propen-1-yl]oxy]-,methyl ester, (3b,16b,17a,18b,20a)- cas no:24815-24-5

NameYohimban-16-carboxylicacid,11,17-dimethoxy-18-[[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propen-1-yl]oxy]-,methyl ester, (3b,16b,17a,18b,20a)-
CAS24815-24-5
Synonyms3b,20a-Yohimban-16b-carboxylic acid, 18b-hydroxy-11,17a-dimethoxy-, methyl ester, 3,4,5-trimethoxycinnamate(ester) (8CI); Rescinnamine (6CI); Yohimban-16-carboxylic acid,11,17-dimethoxy-18-[[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]oxy]-,methyl ester, (3b,16b,17a,18b,20a)- (9CI);Benz[g]indolo[2,3-a]quinolizine, yohimban-16-carboxylic acid deriv.;3,4,5-Trimethoxycinnamoyl methyl reserpate; Anaprel; Apoterin; Apoterin S;Cartric; Cinnaloid; Methyl trimethoxycinnamoylreserpate; Moderil; NSC 15628;O-(3,4,5-Trimethoxy-trans-cinnamoyl) methyl reserpate; Rescinnamin; Rescisan;Resealoid; Reserpic acid methyl ester 3,4,5-trimethoxycinnamate; Reserpinine;Reserpinine (C35 alkaloid); Scinnamina
EINECS(EC#)246-471-8
Molecular FormulaC35H42 N2 O9
Molecular Weight634.79

Appearancewhite to cream powder
refractive index1.621

Hazardclass6.1(b)

Safety

The Risk Statements of Rescinnamine (CAS NO.24815-24-5):R25 :Toxic if swallowed.
Safety Statements: S22:Do not breathe dust. S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) 
RIDADR: 1544
HazardClass: 6.1(b)
PackingGroup: III
Poison by intravenous and intraperitoneal routes. Moderately toxic by ingestion and subcutaneous routes. Human systemic effects by ingestion: olfactory changes, somnolence, and antipsychotic effects. Experimental reproductive effects. When heated to decomposition it emits toxic NO_x.

The toxicity of Rescinnamine (CAS NO.24815-24-5):

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
guinea pig	LDLo	intravenous	35mg/kg (35mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 600, 1973.
human	TDLo	oral	4ug/kg/D (0.004mg/kg)	SENSE ORGANS AND SPECIAL SENSES: OTHER CHANGES: OLFACTION BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ANTIPSYCHOTIC	"Toxicology of Drugs and Chemicals," Deichmann, W.B., New York, Academic Press, Inc., 1969Vol. -, Pg. 517, 1969.
mouse	LD50	intraperitoneal	65mg/kg (65mg/kg)		French Medicament Patent Document. Vol. #5226M,
mouse	LD50	intravenous	56mg/kg (56mg/kg)		U.S. Army Armament Research & Development Command, Chemical Systems Laboratory, NIOSH Exchange Chemicals. Vol. NX#00965,
mouse	LD50	oral	1420mg/kg (1420mg/kg)		"Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 109, 1972.
mouse	LD50	subcutaneous	263mg/kg (263mg/kg)		French Medicament Patent Document. Vol. #5226M,
rat	LD50	intraperitoneal	250mg/kg (250mg/kg)		Drugs in Japan Vol. 6, Pg. 898, 1982.
rat	LD50	oral	1gm/kg (1000mg/kg)		Drugs in Japan Vol. 6, Pg. 898, 1982.
rat	LD50	subcutaneous	540mg/kg (540mg/kg)		Drugs in Japan Vol. 6, Pg. 898, 1982.